GlassScriptPhysician profile
Raul A Santos
NPI 1013926039
$8,375.44
in general payments reported to CMS, 2019-2025
37 companies · $1,494 in 2025
The $1,494 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,072 · 2020: $627 · 2021: $1,213 · 2022: $1,152 · 2023: $1,114 · 2024: $1,703 · 2025: $1,494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,311.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,030.19 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $897.03 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $749.06 | 2019-2025 | |
| Amgen INC. | $677.60 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $642.46 | 2022-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $511.56 | 2019-2025 | Jardiance |
| Heartflow, INC. | $432.87 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $388.14 | 2019-2025 | Lifevest |
| Abbott Laboratories | $379.30 | 2020-2025 | Jot Dx, Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Janssen Pharmaceuticals, INC | $339.15 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $333.17 | 2019-2025 | Farxiga |
| Abiomed | $208.31 | 2019-2025 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $184.43 | 2021-2025 | |
| Esperion Therapeutics, INC. | $173.57 | 2020-2025 | Nexletol |
| Amarin Pharma, INC. | $173.44 | 2019-2023 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $158.70 | 2019-2024 | |
| Scpharmaceuticals INC. | $109.66 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $109.27 | 2022-2025 | Onpattro, Amvuttra |
| Astellas Pharma US INC | $100.21 | 2019-2021 | |
| Novo Nordisk INC | $85.42 | 2019-2025 | Wegovy |
| Lundbeck LLC | $79.55 | 2019-2021 | |
| Gilead Sciences, INC. | $69.03 | 2019 | |
| Cvrx, INC. | $68.58 | 2024 | Barostim Neo System |
| Philips North America LLC | $67.02 | 2023-2025 | Extended Holter, (Ck4) Mcot |
| Boston Scientific Corporation | $63.96 | 2022-2024 | Latitude Communicator Power Supply |
| Arbor Pharmaceuticals, INC. | $58.57 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $55.04 | 2019-2024 | Opsumit |
| Medtronic, INC. | $42.45 | 2021-2023 | Onyx Frontier |
| Abbvie INC. | $27.50 | 2023 | Teflaro |
| Kestra Medical Technology Services, INC. | $27.11 | 2025 | Assure Wcd |
| Biotronik INC. | $25.50 | 2025 | Amvia Edge |
| Impulse Dynamics (USA) INC. | $21.97 | 2024 | Optimizer |
| Kiniksa Pharmaceuticals International, Plc | $21.03 | 2024 | Arcalyst |
| Agepha Pharma Fz LLC | $18.28 | 2024 | Lodoco |
| Inspire Medical Systems, INC. | $17.27 | 2025 | Inspire |
| Azurity Pharmaceuticals, INC. | $15.02 | 2025 | |
| Allergan, INC. | $14.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raul Santos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.